Avondale Partners Downgrades Diplomat Pharmacy (DPLO) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices jump after Trump threatens to hit Iran 'very hard'
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- Hershey appoints State Farm executive Joe Park to board of directors
Diplomat Announces 3rd Quarter Financial Results
November 2, 2016 4:17 PM EDTFLINT, Mich., Nov. 2, 2016 /PRNewswire/ --Â Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended September 30, 2016. Â All comparisons, unless otherwise noted, are to the quarter ended September 30, 2015.
Third Quarter 2016 Highlights include:
Revenue of $1,181 million, an increase of 25% or $234 million 12% organic revenue growth Total prescriptions dispensed of 266,000, an increase of 9% Gross margin of 6.6% versus 8.0% Gross profit per prescription dispensed of $289, compared to $301... More